Condition
Norwalk Gastroenteritis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Norovirus Bivalent Gi1 Gii4 Vaccinemiddle
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Phase 1 (1)
Phase 2 (1)
Phase 3 (1)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT05916326Phase 3Completed
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
NCT04941261Phase 2Unknown
Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)
NCT04188691Phase 1CompletedPrimary
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
Showing all 3 trials
Research Network
Common Treatments
- Norovirus Bivalent Gi1 Gii4 Vaccinemiddle1
- Highdose Norovirus Bivalent Gi1 Gii4 Vaccine1
- Human Norovirus Bivalent Gⅰ1gⅱ4vaccinerecombinant Hansenula Polymorpha1
- Norovirus Bivalent Gi1 Gii4 Vaccinelow1
- Middledose Norovirus Bivalent Gi1 Gii4 Vaccine1
Active Sponsors
- National Vaccine and Serum Institute, China3
- Lanzhou Institute of Biological Products Co., Ltd3
- Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.2
- Zhengzhou University2
Related Conditions
- Norovirus Infections3